Sarah D. Kim

Sarah D. Kim

Auto-generated profile, based on publicly available information

Sarah D. Kim

University of Pennsylvania

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in The American Journal of Bioethics
Verified
Journal Article
Open access
FBFelix R De Bie
Felix R De Bie
SKSarah D. Kim
Sarah D. Kim
SBSourav K. Bose
Sourav K. Bose
PNPamela Nathanson
Pamela Nathanson
EPEmily A. Partridge
Emily A. Partridge
CFChris Feudtner
Chris Feudtner
Since the early 1980’s, with the clinical advent of in vitro fertilization resulting in so-called “test tube babies,” a wide array of ethical considerations and concerns regarding artificial womb technology (AWT) have been described. Recent breakthroughs in the development of extracorporeal neonatal life support by means of AWT have reinitiated ethical interest about this topic with a sense of urgency. Most of the recent ethical literature on the topic, however, pertains not to the more imminent scenario of a physiologically improved method of neonatal care through AWT, but instead to the remote scenario of “complete ectogenesis” that imagines human gestation occurring entirely outside of the womb. This scoping review of the ethical literature on AWT spans from more abstract concerns about complete ectogenesis to more immediate concerns about the soon-to-be-expected clinical life support of what we term the fetal neonate or fetonate. Within an organizing framework of different stages of human gestational development, from conception to the viable premature infant, we discuss both already identified and newly emerging ethical considerations and concerns regarding AWT and the care of the fetonate.

31 July 2023 in Bioethics Open Research
Verified
Journal Article
Open access
SKSarah Kim
Sarah Kim
PNPamela Nathanson
Pamela Nathanson
CFChris Feudtner
Chris Feudtner
Background: Extreme pharmaceutical prices in the United States, their causes, and their ethical implications have been the subject of extensive research and criticism. What has often been overlooked, however, is that the pharmaceutical industry itself often uses ethics language and concepts when offering explanations for their prices, a framing that has not yet been adequately assessed in the context of industry actions. Methods: We conducted an argument analysis of publicly available pharmaceutical industry reports and U.S. Congressional testimony to extract commonly occurring claims regarding their pricing. Results: Starting with the argument that drug research and development are costly, the claims and justifications made in these reports and testimony often invoke common ethical concepts such as benefit, harm, fairness, and autonomy. The arguments and associated rhetoric are, however, often self-contradictory or poorly reflected in the reality of pharmaceutical companies’ actions and experiences in the marketplace. Conclusions: By delineating companies’ public-facing ethics language and identifying hypocritical discrepancies between industry rhetoric and actions.